Open an account

Virpax Pharmaceuticals

VRPX · NASDAQ

$0.0008−$0.0002 (−20.00%)TodayMarket closed ·
No price history for this range.

About VRPX

Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. The company is headquartered in Berwyn, Pennsylvania and currently employs 2 full-time employees. The company went IPO on 2021-02-17. The firm is focused on developing novel and proprietary drug delivery systems across various pain indications. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical grade cannabidiol (CBD) for the management of rare pediatric epilepsy.

Employees
2
Headquarters
Berwyn, Pennsylvania
Listed
Feb 17, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
virpaxpharma.com

VRPX key statistics

Market cap
994
Price-earnings ratio
0.00
Dividend yield
—
Average volume
109
Volume
4
Open price
$0.0008
High today
$0.0008
Low today
$0.0008
52 Week high
$0.10
52 Week low
$0.00

Virpax Pharmaceuticals (VRPX) at a glance

As of Oct 20, 2026, Virpax Pharmaceuticals (VRPX) shares are priced at $0.0008, giving the company a market cap of 994 and a price-to-earnings ratio of 0.00.

Volume so far is 4 shares, below the average of 109 shares a day.

Over the past year Virpax Pharmaceuticals has ranged from $0.00 to $0.10, and now sits 1% of the way up that range.

Virpax Pharmaceuticals met or beat analyst EPS estimates in 1 of the last 7 quarters. In Q4 FY24 it reported -$20.00 per share against an estimate of -$6.89.

VRPX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 7 quarters, by 21.9% on average.

  1. Q2 FY22: reported -$125.00 per share against an estimate of -$112.20
  2. Q3 FY22: reported -$162.50 per share against an estimate of -$114.75
  3. Q3 FY23: reported -$127.50 per share against an estimate of -$66.30
  4. Q4 FY23: reported -$97.50 per share against an estimate of -$68.85
  5. Q2 FY24: reported -$43.75 per share against an estimate of -$39.01
  6. Q3 FY24: reported -$10.75 per share against an estimate of -$13.77
  7. Q4 FY24: reported -$20.00 per share against an estimate of -$6.89

VRPX news

  • 11 Health Care Stocks Moving In Thursday's Intraday Session

  • Rishabh Mishra

    US Stocks Likely To Open Lower After Fed Decision: Any Pullback In Equities 'Offers An Opportunity,' Says Expert

  • Press releaseBusiness Wire

    Virpax Pharmaceuticals Announces Reverse Stock Split

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseBusiness Wire

    Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releaseBusiness Wire

    Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

  • Press releaseBusiness Wire

    Virpax's NES100 to be Presented at The Society of Toxicology by NCATS

Similar companies

Companies in the same industry as Virpax Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.